scaling up

Houston startup advances in Chevron's unique business accelerator

Currently, methane leak detection requires human evaluation. With this innovative new company's tech, this process can be automated. Photo via Getty Images

A Houston startup that is developing a technology to detect methane leaks has moved on to phase two in Chevron's unique business accelerator.

Aquanta Vision Technologies, a Houston-based climate-tech startup, was selected to participate in the scale-up phase of Chevron Studio, a Houston program that matches entrepreneurs with technologies to turn them into businesses. Aquanta's computer vision software completely automates the identification of methane in optical gas imaging, or OGI. The technology originated from Colorado State University and CSU STRATA Technology Transfer.

Babur Ozden, a tech startup entrepreneur, along with Marcus Martinez, the lead inventor and Dan Zimmerle, co-inventor and director of METEC at CSU Energy Institute, came up with the technology to identify the presence and motion of methane in live video streams. Currently, this process of identifying methane requires a human camera operator to interpret the images. This can often be unreliable in the collection of emissions data.

Babur Ozden is the founder of Aquanta Vision. Photo via LinkedIn

Aquanta’s technology requires no human intervention and is universally compatible with all OGI cameras. Currently, only about 10 percent of the 20.5 million surveys done worldwide use this type of technology as it is extremely expensive to produce. Ozden said he hopes Aquanta will change that model.

“What we are doing — we are democratizing this feature, this capability, independent of the camera make and model,” Ozden tells EnergyCapital.

Aquanta’s software will be downloadable from App stores to the technician’s computers or phones.

“Our goal is to eliminate the absolute reliance of human interpretation and to give operators a chance to make detections faster and more accurately,” Ozden says.

“Our ultimate ambition is to reduce our footprint.” he continues. “Companies like Chevron and other leading players in the oil and gas industry are becoming much more committed (to reducing emissions)."

Aquanta will now test its software under various scenarios and develop an early commercial version of the product. In the next and final phase of the program, the company will begin marketing the technology for commercial use.

The goal of Chevron Studio is to take innovative new technologies out of the labs at universities and to scale them up to commercial ventures. The company takes the intellectual property developed at these labs and provides a platform to match entrepreneurs with the technology. The program provides funding to take the technologies from the very beginning to pilot and field trials. The National Renewable Energy Laboratory, or NREL, manages Chevron Studio and works closely with the entrepreneurs to guide them through the program.

Gautam Phanse, the strategic relations manager for Chevron Technology Ventures says he was impressed with Ozden’s background as an entrepreneur and in the technology he brought to the table.

“We are looking at experienced entrepreneurs. People who can take an idea and stand on their own and develop it into a business,” he tells EnergyCapital.

Earlier this year, Phanse spoke to InnovationMap about Chevron Studio and its mission to match entrepreneurs with promising technologies coming out of universities and labs. He said the current focus areas for Chevron Studio are: carbon utilization, hydrogen and renewable energy, energy storage systems and solutions for circular economy.

------

This article originally ran on EnergyCapital.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted